Murine models of Alzheimer's disease and their use in developing immunotherapies
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is one of the categories of neurodegenerative diseases characterized by a conformational change of a normal protein into a pathological conformer with a high β-sheet content that renders it resistant to degradation and neurotoxic. In AD, the normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The oligomeric forms of Aβ are thought to be the most toxic, while fibrillar Aβ becomes deposited as amyloid plaques and congophilic angiopathy, which both serve as neuropathological markers of the disease. An additional important feature of AD is the accumulation of abnormally phosphorylated tau as soluble toxic oligomers and as neurofibrillary tangles. Many therapeutic interventions are under investigation to prevent and treat AD. The testing of these diverse approaches to ameliorate AD pathology has been made possible by the existence of numerous transgenic mouse models which each mirror specific aspects of AD pathology. None of the current murine models is a perfect match of the human disease. Perhaps the most exciting of the therapeutic approaches being developed is immunomodulation targeting the aggregating proteins, Aβ and tau. This type of AD therapy is currently being assessed in many transgenic mouse models, and promising findings have led to clinical trials. However, there is a discrepancy between results in murine models and ongoing clinical trials, which highlight the limitations of these models and also of our understanding of the underlying etiology and pathogenesis of AD. Because of these uncertainties, Tg models for AD are continuously being refined with the aim to better understand the disease and to enhance the predictive validity of potential treatments such as immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 3×
“[35], used the Indiana mutation V717F under the control of the PDGF promoter.”
BackgroundMethodSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“In addition, it has been shown that reducing the level of endogenous mouse tau can prevent behavioral deficits in APP Tg mice without affecting Aβ levels [25] and that exogenous Aβ extracted from AD Tg mice can accelerate plaque deposition in predisposed young Tg mice [26].”
BackgroundMucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 2×
“V717F 695 PDGF-β 10-fold + 7 months (MWM) 12 months 6 months [94]”
BackgroundTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Research works printed but not linked: 134
- Rafii, 2009, Recent developments in Alzheimer's disease therapeutics, BMC Med., 7, 7, 10.1186/1741-7015-7-7 · DOI · Paper page
- Biran, 2009, Pharmacotherapeutic targets in Alzheimer's disease, J. Cell. Mol. Med., 13, 61, 10.1111/j.1582-4934.2008.00595.x · DOI · Paper page
- Wisniewski, 2010, Vaccination as a therapeutic approach for Alzheimer's disease, Mt. Sinai J. Med., 77, 17, 10.1002/msj.20156 · DOI · Paper page
- Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
- Hardy, 2006, A hundred years of Alzheimer's disease research, Neuron, 52, 3, 10.1016/j.neuron.2006.09.016 · DOI · Paper page
- Oddo, 2003, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron, 39, 409, 10.1016/S0896-6273(03)00434-3 · DOI · Paper page
- King, 2006, tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid, J. Cell Biol., 175, 541, 10.1083/jcb.200605187 · DOI · Paper page
- Sigurdsson, 1996, Local and distant histopathological effects of unilateral amyloid-beta 25–35 injections into the amygdala of young F344 rats, Neurobiol. Aging, 17, 893, 10.1016/S0197-4580(96)00169-8 · DOI
- Sigurdsson, 1997, Bilateral injections of amyloid-beta 25–35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects, Neurobiol. Aging, 18, 591, 10.1016/S0197-4580(97)00154-1 · DOI
- Sigurdsson, 2001, Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice, Am. J. Pathol., 159, 439, 10.1016/S0002-9440(10)61715-4 · DOI · Paper page
- Morgan, 2000, Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease, Nature, 408, 982, 10.1038/35050116 · DOI · Paper page
- Sigurdsson, 2004, An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives, J. Neurosci., 24, 6277, 10.1523/JNEUROSCI.1344-04.2004 · DOI · Paper page
- Asuni, 2006, Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice, Eur. J. Neurosci., 24, 2530, 10.1111/j.1460-9568.2006.05149.x · DOI · Paper page
- Blurton-Jones, 2006, Pathways by which Abeta facilitates tau pathology, Curr. Alzheimer Res., 3, 437, 10.2174/156720506779025242 · DOI · Paper page
- McKee, 2008, Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice, Brain Res., 1207, 225, 10.1016/j.brainres.2008.01.095 · DOI · Paper page
- Shioi, 2007, FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta, J. Neurochem., 101, 674, 10.1111/j.1471-4159.2006.04391.x · DOI · Paper page
- Masliah, 2001, Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, J. Neuropathol. Exp. Neurol., 60, 357, 10.1093/jnen/60.4.357 · DOI · Paper page
- Hsiao, 1996, Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice., Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
- Fryer, 2003, Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice, J. Neurosci., 23, 7889, 10.1523/JNEUROSCI.23-21-07889.2003 · DOI · Paper page
- Frautschy, 1998, Microglial response to amyloid plaques in APPsw transgenic mice, Am. J. Pathol., 152, 307
- Tan, 1999, Microglial activation resulting from CD40–CD40L interaction after beta-amyloid stimulation, Science, 286, 2352, 10.1126/science.286.5448.2352 · DOI · Paper page
- Pappolla, 1998, Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo, Am. J. Pathol., 152, 871
- Smith, 1998, Amyloid beta deposition in Alzheimer transgenic mice is associated with oxidative stress, J. Neurochem., 70, 2212, 10.1046/j.1471-4159.1998.70052212.x · DOI · Paper page
- Arendash, 2001, Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes, Brain Res., 891, 42, 10.1016/S0006-8993(00)03186-3 · DOI · Paper page
- Tagliavini, 1991, Amyloid protein of Gerstmann–Straussler–Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N- terminal glycine at codon 58, EMBO J., 10, 513, 10.1002/j.1460-2075.1991.tb07977.x · DOI · Paper page
- Rockenstein, 2001, Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42), J. Neurosci. Res., 66, 573, 10.1002/jnr.1247 · DOI · Paper page
- Moechars, 1999, Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain, J. Biol. Chem., 274, 6483, 10.1074/jbc.274.10.6483 · DOI · Paper page
- Kumar-Singh, 2000, Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation, Neurobiol. Dis., 7, 9, 10.1006/nbdi.1999.0272 · DOI · Paper page
- Brouwers, 2008, Molecular genetics of Alzheimer's disease: an update, Ann. Med., 40, 562, 10.1080/07853890802186905 · DOI · Paper page
- Wolfe, 2009, gamma-Secretase in biology and medicine, Semin. Cell Dev. Biol., 20, 219, 10.1016/j.semcdb.2008.12.011 · DOI
- Duff, 1996, Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1, Nature, 383, 710, 10.1038/383710a0 · DOI · Paper page
- Holcomb, 1998, Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat. Med., 4, 97, 10.1038/nm0198-097 · DOI · Paper page
- Wilhelmus, 2007, Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer's disease, Mol. Neurobiol., 35, 203, 10.1007/s12035-007-0029-7 · DOI · Paper page
- Wisniewski, 2008, Preventing Aβ fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors, BMC Neurosci., 9, 1, 10.1186/1471-2202-9-S2-S5 · DOI
- Prelli, 1988, Differences between vascular and plaque core amyloid in Alzheimer's disease, J. Neurochem., 51, 648, 10.1111/j.1471-4159.1988.tb01087.x · DOI · Paper page
- Mahley, 2009, Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches, Ann. Neurol., 65, 623, 10.1002/ana.21736 · DOI
- Wisniewski, 1993, Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid, Biochem. Biophys. Res. Commun., 192, 359, 10.1006/bbrc.1993.1423 · DOI · Paper page
- Wisniewski, 1994, Alzheimer's disease and soluble Aβ, Neurobiol. Aging, 15, 143, 10.1016/0197-4580(94)90105-8 · DOI
- Bales, 1999, Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease, Proc. Natl Acad. Sci. U. S. A., 96, 15233, 10.1073/pnas.96.26.15233 · DOI · Paper page
- Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8 · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
- Calon, 2004, Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model, Neuron, 43, 633, 10.1016/j.neuron.2004.08.013 · DOI · Paper page
- Dziewczapolski, 2009, Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease, J. Neurosci., 29, 8805, 10.1523/JNEUROSCI.6159-08.2009 · DOI · Paper page
- Colton, 2006, NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 103, 12867, 10.1073/pnas.0601075103 · DOI · Paper page
- Wilcock, 2009, Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease, J. Neurosci., 29, 7957, 10.1523/JNEUROSCI.1339-09.2009 · DOI · Paper page
- Zhang-Nunes, 2006, The cerebral beta-amyloid angiopathies: hereditary and sporadic, Brain Pathol., 16, 30, 10.1111/j.1750-3639.2006.tb00559.x · DOI · Paper page
- Domnitz, 2005, Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease, J. Neuropathol. Exp. Neurol., 64, 588, 10.1097/01.jnen.0000171644.00180.fc · DOI · Paper page
- Davis, 2006, Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice, Neurobiol. Aging, 27, 946, 10.1016/j.neurobiolaging.2005.05.031 · DOI
- Xu, 2007, Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice, Neuroscience, 146, 98, 10.1016/j.neuroscience.2007.01.043 · DOI
- Levy, 1990, Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type, Science, 248, 1124, 10.1126/science.2111584 · DOI · Paper page
- Kumar-Singh, 2009, Hereditary and sporadic forms of Abeta-cerebrovascular amyloidosis and relevant transgenic mouse models, Int. J Mol. Sci., 10, 1872, 10.3390/ijms10041872 · DOI · Paper page
- Attems, 2004, Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology—a pilot study, Acta Neuropathol. (Berl), 107, 83, 10.1007/s00401-003-0796-9 · DOI · Paper page
- Wilcock, 2009, Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease, Neuroscience, 159, 1055, 10.1016/j.neuroscience.2009.01.023 · DOI · Paper page
- Zilka, 2009, Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies, Acta Neuropathol., 118, 71, 10.1007/s00401-009-0499-y · DOI
- Gotz, 2000, In vivo analysis of wild-type and FTDP-17 tau transgenic mice, Ann. NY Acad. Sci., 920, 126, 10.1111/j.1749-6632.2000.tb06914.x · DOI · Paper page
- Ishihara, 2001, Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice, Am. J. Pathol., 158, 555, 10.1016/S0002-9440(10)63997-1 · DOI · Paper page
- Tanemura, 2001, Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau, Neurobiol. Dis., 8, 1036, 10.1006/nbdi.2001.0439 · DOI · Paper page
- Egashira, 2005, Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice, Brain Res., 1059, 7, 10.1016/j.brainres.2005.08.004 · DOI
- Lee, 2005, Transgenic animal models of tauopathies, Biochim. Biophys. Acta, 1739, 251, 10.1016/j.bbadis.2004.06.014 · DOI · Paper page
- Murakami, 2006, Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation, Am. J Pathol, 169, 1365, 10.2353/ajpath.2006.051250 · DOI
- Rosenmann, 2008, A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics, Exp. Neurol., 212, 71, 10.1016/j.expneurol.2008.03.007 · DOI
- Schindowski, 2006, Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits, Am. J. Pathol., 169, 599, 10.2353/ajpath.2006.060002 · DOI · Paper page
- Taniguchi, 2005, Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation, FEBS Lett., 579, 5704, 10.1016/j.febslet.2005.09.047 · DOI · Paper page
- Mastrangelo, 2008, Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice, BMC Neurosci., 9, 81, 10.1186/1471-2202-9-81 · DOI · Paper page
- Boutajangout, 2008, Presenilin 1 mutation promotes tau phosphorylation and aggregation in a novel Alzheimer's disease mouse model, Alz.Dementia, 4, T185, 10.1016/j.jalz.2008.05.504 · doi:10.1016/j.jalz.2008.05.504
- Boutajangout, 2009, Influence of presenilin mutation on tau pathology in novel Alzheimer's disease mouse model, Alz Dementia, 5, P445, 10.1016/j.jalz.2009.04.919 · doi:10.1016/j.jalz.2009.04.919
- Solomon, 1997, Disaggregation of Alzheimer β-amyloid by site-directed mAb, Proc. Natl Acad. Sci. U. S. A., 94, 4109, 10.1073/pnas.94.8.4109 · DOI · Paper page
- Solomon, 2007, Antibody-mediated immunotherapy for Alzheimer's disease, Curr. Opin. Investig. Drugs, 8, 519
- Frenkel, 2003, Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization, Vaccine, 21, 1060, 10.1016/S0264-410X(02)00609-6 · DOI
- Lavie, 2004, EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials, J. Mol. Neurosci., 24, 105, 10.1385/JMN:24:1:105 · DOI
- Schiltz, 2004, Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease, J. Mol. Med., 82, 706, 10.1007/s00109-004-0570-z · DOI
- Lemere, 2001, Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease, DNA Cell Biol., 20, 705, 10.1089/10445490152717569 · DOI · Paper page
- Sigurdsson, 2001, Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice, Am. J. Pathol., 159, 439, 10.1016/S0002-9440(10)61715-4 · DOI · Paper page
- Sigurdsson, 2002, Immunization for Alzheimer's disease, Drug Dev. Res., 56, 135, 10.1002/ddr.10068 · DOI
- Wisniewski, 2005, Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease, Brain Pathol., 15, 72, 10.1111/j.1750-3639.2005.tb00102.x · DOI · Paper page
- Pride, 2008, Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis, Neurodegener. Dis., 5, 194, 10.1159/000113700 · DOI · Paper page
- Wisniewski, 2005, Practice point commentary on, “Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial”, Nat. Clin. Pract. Neurol., 1, 84, 10.1038/ncpneuro0019 · DOI
- Boche, 2008, The role of the immune system in clearance of Aβ from the brain, Brain Pathol., 18, 267, 10.1111/j.1750-3639.2008.00134.x · DOI · Paper page
- Bombois, 2007, Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia, Arch. Neurol., 64, 583, 10.1001/archneur.64.4.583 · DOI · Paper page
- Ferrer, 2004, Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease, Brain Pathol., 14, 11, 10.1111/j.1750-3639.2004.tb00493.x · DOI · Paper page
- Masliah, 2005, Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease, Neurol., 64, 129, 10.1212/01.WNL.0000148590.39911.DF · DOI · Paper page
- Boche, 2008, Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain, Brain, 131, 3299, 10.1093/brain/awn261 · DOI · Paper page
- Sadowski, 2007, Disease modifying approaches for Alzheimer's pathology, Curr. Pharm. Des., 13, 1943, 10.2174/138161207781039788 · DOI · Paper page
- Hock, 2003, Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease, Neuron, 38, 547, 10.1016/S0896-6273(03)00294-0 · DOI · Paper page
- Hock, 2002, Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease, Nat. Med., 8, 1270, 10.1038/nm783 · DOI · Paper page
- Cribbs, 2003, Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid, Int. Immunol., 15, 505, 10.1093/intimm/dxg049 · DOI · Paper page
- Maier, 2006, Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response, J. Neurosci., 26, 4717, 10.1523/JNEUROSCI.0381-06.2006 · DOI · Paper page
- Agadjanyan, 2005, Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide, J. Immunol., 174, 1580, 10.4049/jimmunol.174.3.1580 · DOI · Paper page
- Zamora, 2006, Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice, J. Immunol., 177, 2662, 10.4049/jimmunol.177.4.2662 · DOI
- Chackerian, 2006, Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses, Vaccine, 24, 6321, 10.1016/j.vaccine.2006.05.059 · DOI
- Jennings, 2008, The coming of age of virus-like particle vaccines, Biol. Chem., 389, 521, 10.1515/BC.2008.064 · DOI · Paper page
- Movsesyan, 2008, Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine—a novel immunotherapeutic strategy, PLoS. ONE., 3, e2124, 10.1371/journal.pone.0002124 · DOI · Paper page
- Head, 2008, A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta, J Neurosci., 28, 3555, 10.1523/JNEUROSCI.0208-08.2008 · DOI · Paper page
- Weiner, 2000, Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease, Ann. Neurol., 48, 567, 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W · DOI · Paper page
- Lemere, 2002, Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants, Neurobiol Aging, 23, 991, 10.1016/S0197-4580(02)00127-6 · DOI
- Hara, 2004, Development of a safe oral Ab vaccine using recombinant adeno-associated virus vector for Alzheimer's disease, J. Alz. Dis., 6, 483, 10.3233/JAD-2004-6504 · DOI · Paper page
- Seabrook, 2006, Dendrimeric Abeta1–15 is an effective immunogen in wildtype and APP-tg mice, Neurobiol Aging, 1
- Nikolic, 2007, Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage, Proc. Natl. Acad. Sci. U. S. A, 104, 2507, 10.1073/pnas.0609377104 · DOI · Paper page
- Boutajangout, 2009, Lack of cognitive impairment and reduced Aβ burden in Tg2576 mice following acute prophylactic oral immunization with an Aβ derivative, J. Alz. Dis., 18, 961, 10.3233/JAD-2009-1204 · DOI
- McLaurin, 2002, Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis, Nat. Med., 8, 1263, 10.1038/nm790 · DOI · Paper page
- Levites, 2006, Anti-Aβ42 and anti-Aβ40 specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model, J. Clin. Invest, 116, 193, 10.1172/JCI25410 · DOI · Paper page
- Wilcock, 2004, Passive immunization against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage, J. Neuroinflammation, 1, 24, 10.1186/1742-2094-1-24 · DOI
- Wilcock, 2007, Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid, Neuroscience, 144, 950, 10.1016/j.neuroscience.2006.10.020 · DOI
- Petrushina, 2008, Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice, J Neuroinflammation., 5, 42, 10.1186/1742-2094-5-42 · DOI
- Kramer, 2002, Executive dysfunction in subcortical ischaemic vascular disease, J Neurol Neurosurg. Psychiatry, 72, 217, 10.1136/jnnp.72.2.217 · DOI · Paper page
- Sigurdsson, 2008, Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies, J Alzheimers. Dis., 15, 157, 10.3233/JAD-2008-15202 · DOI · Paper page
- Noble, 2009, Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding, Prion., 3, 10.4161/pri.3.2.8820 · DOI · Paper page
- Kayed, 2009, Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders, Curr. Opin. Immunol., 21, 359, 10.1016/j.coi.2009.05.001 · DOI
- Sigurdsson, 2009, Tau-focused immunotherapy for Alzheimer's disease and related tauopathies, Curr. Alzheimer Res., 6, 446, 10.2174/156720509789207930 · DOI · Paper page
- Goedert, 1989, Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease, Neuron, 3, 519, 10.1016/0896-6273(89)90210-9 · DOI · Paper page
- Utton, 2005, Molecular motors implicated in the axonal transport of tau and alpha-synuclein, J. Cell. Sci., 118, 4645, 10.1242/jcs.02558 · DOI · Paper page
- Magnani, 2007, Interaction of tau protein with the dynactin complex, EMBO J., 26, 4546, 10.1038/sj.emboj.7601878 · DOI · Paper page
- Morishima-Kawashima, 1995, Hyperphosphorylation of tau in PHF, Neurobiol. Aging, 16, 365, 10.1016/0197-4580(95)00027-C · DOI · Paper page
- Brion, 1986, Alzheimer's disease and tau proteins, Lancet, 2, 1098, 10.1016/S0140-6736(86)90495-2 · DOI
- Brion, 2006, Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer's disease, J. Alzheimers Dis., 9, 177, 10.3233/JAD-2006-9S321 · DOI
- Wang, 2008, Microtubule-associated protein tau in development, degeneration and protection of neurons, Prog. Neurobiol., 85, 148, 10.1016/j.pneurobio.2008.03.002 · DOI · Paper page
- Buee, 2000, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Brain Res. Rev., 33, 95, 10.1016/S0165-0173(00)00019-9 · DOI · Paper page
- Baumann, 1993, Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5, FEBS Lett., 336, 417, 10.1016/0014-5793(93)80849-P · DOI · Paper page
- Hamdane, 2003, Mitotic-like tau phosphorylation by p25–Cdk5 kinase complex, J. Biol. Chem., 278, 34026, 10.1074/jbc.M302872200 · DOI · Paper page
- Ren, 2009, Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates, Nat. Cell Biol., 11, 219, 10.1038/ncb1830 · DOI · Paper page
- Aguzzi, 2009, Cell biology: beyond the prion principle, Nature, 459, 924, 10.1038/459924a · DOI · Paper page
- Wisniewski, 1995, Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis, Am. J. Pathol., 147, 238
- Jucker, 2008, Cerebral and peripheral amyloid phagocytes—an old liaison with a new twist, Neuron, 59, 8, 10.1016/j.neuron.2008.06.014 · DOI · Paper page
- Butovsky, 2007, Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model, Eur. J. Neurosci., 26, 413, 10.1111/j.1460-9568.2007.05652.x · DOI · Paper page
- Obregon, 2008, CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation, Neurobiol. Dis., 29, 336, 10.1016/j.nbd.2007.09.009 · DOI
- Lee, 2006, Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice, J. Biol. Chem., 281, 4292, 10.1074/jbc.M511018200 · DOI · Paper page
- Moretto, 2007, Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide, J. Biol. Chem., 282, 11436, 10.1074/jbc.M609690200 · DOI · Paper page
- Mamikonyan, 2007, Anti-A beta 1–11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers, J. Biol. Chem., 282, 22376, 10.1074/jbc.M700088200 · DOI · Paper page
- Maji, 2009, Functional amyloids as natural storage of peptide hormones in pituitary secretory granules, Science, 325, 328, 10.1126/science.1173155 · DOI · Paper page
- Kayed, 2003, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science, 300, 486, 10.1126/science.1079469 · DOI · Paper page
- Wisniewski, 2009, Immunotherapy targeting abnormal protein conformation, Alz. Dementia, 5, P113, 10.1016/j.jalz.2009.05.354 · DOI
- Sigurdsson, 2008, Tau immunotherapy prevents cognitive decline and clears pathological tau in a mouse model, Alz Dementia, 4, T191, 10.1016/j.jalz.2008.05.530 · doi:10.1016/j.jalz.2008.05.530
- Wisniewski, 2007, Therapeutic approaches for prion and Alzheimer's diseases, FEBS J., 274, 3784, 10.1111/j.1742-4658.2007.05919.x · DOI
- Goni, 2008, High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice, Neurosci., 153, 679, 10.1016/j.neuroscience.2008.02.051 · DOI
- Lee, 2005, Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis, FEBS Lett., 579, 2564, 10.1016/j.febslet.2005.03.070 · DOI · Paper page
Cited by
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
“Initial transgenic models expressed wild-type human APP in mice, however, while these transgenic mice had increased Aβ production, they failed to consistently show extensive AD associated neuropathology [14, 34, 117, 172, 173].”
BackgroundInfluentialThe Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442
Synaptic changes in Alzheimer’s disease and its models
Pozueta, J., Lefort, R., & Shelanski, M. L. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.050 · Cited by 307
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284
Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193
Metadata
- Authors
- Wisniewski, T., & Sigurdsson, E. M.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 1802
- Issue
- 10
- Pages
- 847-859
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W2041492570
- Cited by
- 81
- References
- 102
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1056 d)
- Funders
- NIH grants (AG20245, AG15408, AG020197, AG032611)
- Alzheimer's Association
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Murine models of Alzheimer's disease and their use in developing immunotherapies. https://app.cochat.ai/papers/10.1016/j.bbadis.2010.05.004
- The paper
- Wisniewski, T., & Sigurdsson, E. M. (2010). Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2010.05.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.